High Prevalence of Low Vitamin D and Musculoskeletal Complaints in Women with Breast Cancer

Napoli, Nicola; Vattikuti, Swapna; Ma, Cynthia; Rastelli, Antonella; Rayani, Anitha; Donepudi, Ravi; Asadfard, Mohammadreza; Yarramaneni, Jayasree; Ellis, M.; Armamento-Villareal, Reina

doi:10.1111/j.1524-4741.2010.01012.x

Cited by 35 publications

(30 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study has shown that low vitamin D levels are highly prevalent among newly diagnosed breast cancer patients with nearly 44 % with vitamin D insufficiency [150]. As expected, African-Americans are more affected than Caucasians [150]. Clinical trials using vitamin D in cancer patients are lacking.…”

Section: Prevention Of Bone Loss and Fracturesmentioning

confidence: 99%

Cancer-associated bone disease

Rizzoli

Body²,

Brandi³

et al. 2013

Osteoporos Int

128

103

View full text Add to dashboard Cite

Bone is commonly affected in cancer. Cancer-induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer-related bone disease. With evidence-based care pathways, guidelines assist physicians in clinical decision-making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non-communicable diseases, led by cardiovascular diseases and cancers. Bone is a commonly affected organ in cancer, and although the incidence of metastatic bone disease is not well defined, it is estimated that around half of patients who die from cancer in the USA each year have bone involvement. Furthermore, cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances or metastatic bone disease, such as commonly occurs with breast, lung and prostate cancer, or from therapies administered to treat the primary condition thus causing bone loss and fractures. Treatment-induced osteoporosis may occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy, chemotherapy-induced ovarian failure and androgen deprivation therapy. Tumour skeletal-related events include pathologic fractures, spinal cord compression, surgery and radiotherapy to bone and may or may not include hypercalcaemia of malignancy while skeletal complication refers to pain and other symptoms. Some evidence demonstrates the efficacy of various interventions including bone-modifying agents, such as bisphosphonates and denosumab, in preventing or delaying cancer-related bone disease. The latter includes treatment of patients with metastatic skeletal lesions in general, adjuvant treatment of breast and prostate cancer in particular, and the prevention of cancerassociated bone disease. This has led to the development of guidelines by several societies and working groups to assist physicians in clinical decision making, providing them with evidencebased care pathways to prevent skeletal-related events and bone loss. The goal of this paper is to put forth an IOF position paper addressing bone diseases and cancer and summarizing the position papers of other organizations. Epidemiology of cancer-associated bone disease Bone metastasisCancer affects nearly 12.7 million people and is associated with over 7 million deaths in 2008 [1]. Cancer is a rising global health burden and it is estimated that in 2030, cancer deaths will be tallied at over 13 million (World Health Organization (WHO) 2010 Global Status Report [2]). Addressing the morbidity and mortality of cancer is an important public health concern. On purpose, we are limiting our analysis to cancer bone involvement in adults and do not discuss cancer in children.Metastases from cancer are associated with 90 % of cancer deaths [3]. It was estimated that one half of people who die from cancer in the USA have bone involvement [4][5][6]. Different tumou...

show abstract

Section: Prevention Of Bone Loss and Fracturesmentioning

confidence: 99%

Cancer-associated bone disease

Rizzoli

Body²,

Brandi³

et al. 2013

Osteoporos Int

128

103

View full text Add to dashboard Cite

show abstract

“…<20 ng/mL. A recent study showed that low vitamin D levels are highly prevalent among newly diagnosed breast cancer patients with nearly 44 % with vitamin D insufficiency (50,51). However, only few clinical trials evaluated the impact of vitamin D supplementation in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in breast cancer: a secret passage through skeletal muscle and bone health

Persichetti¹

2014

RIO

View full text Add to dashboard Cite

Breast cancer is the most common female cancer diagnosed worldwide. In Italy it represents about 30% of all cancer type in women and 17% of deaths due to malignancies. Neo or adjuvant therapy, which includes external beam radiation, chemotherapy and hormonal therapy (tamoxifen ± LH-RH analogues, aromatase inhibitors) allow early breast cancer patients to reach 10 years survival rate of about 80-85%. The improved prognosis of this subgroup of patients arise new challenges because cancer itself, treatments and age related changes can affect greatly patients' quality of life. Bone loss and osteoporosis are common disorders in patients affected with breast cancer because many systemic therapies for breast cancer interfere with skeletal homeostasis, either through their effects on gonadal steroid hormone production or by inhibiting peripheral aromatization of androgens into estrogens, and cause an increased risk of morbidity and mortality related to skeletal events such as vertebral and spine fractures. Also, age related modifications in body fat and lean mass, with progressive and generalized loss of skeletal muscle mass and strength, characterizing a condition known as sarcopenia, can exacerbate the risk of frailty and adverse outcomes. According to current evidence, a complete clinical evaluation of the breast cancer long survivors is imperative in order to prevent and treat in an early stage any comorbidity (osteoporosis, sarcopenia, metabolic syndrome). This can be achieved only with a multidisciplinary approach, where oncologist, endocrinologist and nutritionist work together to maximize bone and muscle health to enhance the quality of life and to reduce mortality and skeletal events related morbidity.

show abstract

“…In breast cancer patients, osteopenia and osteoporosis mostly occur because of early menopause and vitamin D deficiency, which is then augmented by chemotherapy and hormone replacement therapy [94]. Therefore, breast cancer patients are necessary to suffer a baseline metabolic bone evaluation along with circulating vitamin D levels and bone mineral densitometry [94,95].…”

Section: Vitamin D Deficiency and Breast Cancermentioning

confidence: 99%

Vitamin D, Its Receptor Gene Polymorphism and Breast Cancer

Iqbal¹,

Khan²

2017

A Critical Evaluation of Vitamin D - Clinical Overview

View full text Add to dashboard Cite

Vitamin D is synthesized within skin followed by the peripheral maturation in liver and kidneys. Vitamin D is most essential secosteroid produced its systemic functions via complex with steroid/thyroid nuclear receptor called vitamin D receptor (VDR). The binding of the vitamin D3 to VDR causes conformational changes that permit VDR-RXR heterodimer formation and VDR/ SRC-1 (transcriptional co-activator proteins) interactions. Functional expression and nuclear activation of VDR is necessary to produce its effects upon binding with vitamin D response element (VDRE) on target gene where it causes transcriptional activation resulting in the prevention of breast cancer by inhibiting proliferation, impeding differentiation and stimulating proapoptosis. Season, latitude, pigmentation of skin, aging, sunscreen use, obesity, and smoking all affect the production of vitamin D. In case of vitamin D deficiency or VDR gene polymorphisms, vitamin D responses are altered and probably are involved in the risk of breast cancer. Since many epidemiological, observational and interventional studies have been done to illustrate the role of vitamin D and its receptor gene polymorphism in breast cancer development but controversial findings have been observed. Therefore, the role of vitamin D and its receptor gene polymorphisms in development of breast cancer are still a matter of discussion.

show abstract

High Prevalence of Low Vitamin D and Musculoskeletal Complaints in Women with Breast Cancer

Cited by 35 publications

References 35 publications

Cancer-associated bone disease

Cancer-associated bone disease

Quality of life in breast cancer: a secret passage through skeletal muscle and bone health

Vitamin D, Its Receptor Gene Polymorphism and Breast Cancer

Contact Info

Product

Resources

About